Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311573 | 0.78 | MAOA (0.50) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL1449448 | 0.76 | MAOA (0.48) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL1818127 | 0.76 | MAOA (0.48) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL670717 | 0.76 | MAOA (0.48) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL10576769 | 0.74 | MAOA (0.47) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL84394 | 0.74 | NOS3 (0.65) | MAOABCHENOS3NOS2NOS1 | |
| SCHEMBL7476251 | 0.73 | MAOA (0.45) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL7716195 | 0.72 | MAOA (0.44) | MAOACES1BCHEALDH1A1KDM4E | |
| SCHEMBL1344620 | 0.72 | ALDH1A1 (0.47) | MAOACES1BCHENOS3NOS2 | |
| SCHEMBL12757741 | 0.72 | ALDH1A1 (0.47) | MAOACES1BCHENOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | claimed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | claimed |
| EP-3904343-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | Zhejiang University (CN) | 2021-11-03 | — | — | EP | claimed |
| CN-109516961-B | Aminoquinazolinone and aminoisoquinolinone derivatives and uses thereof | 浙江大学 | 2021-01-01 | — | — | CN | claimed |
| WO-2020134921-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | 浙江大学 | 2020-07-02 | — | — | WO | claimed |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | disclosed |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| US-6770639-B2 | CELL PROLIFERATIVE; AUTOIMMUNE DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| US-4052410-A | YELLOW, PLASTICS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-3979386-A | YELLOW, COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | MAOA 1121/4885CES1 985/4885BCHE 1766/4885 |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | PIK3R5, PIK3CA, PIK3R1 | MAOA 3981/4885CES1 2246/4885BCHE 4287/4885 |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | MAOA 408/4885CES1 2919/4885BCHE 3175/4885 |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | PIK3R5, PIK3CA, PIK3R1 | MAOA 3981/4885CES1 2246/4885BCHE 4287/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | MAOA 1121/4885CES1 985/4885BCHE 1766/4885 |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | MAOA 408/4885CES1 2919/4885BCHE 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.